Collegium Pharmaceutical, Inc. (COLL) Raw materials — Quarterly & Annual

Screener

Raw materials at other companies

Pacira BioSciences, Inc.PCRX

$39.81M-13.2%

BioventusBVS

$18.36M-21.7%

OrganonOGN

$13M-50.0%

Cumberland PharmaceuticalsCPIX

$9.68M-6.7%

Other financials

Income statement

Revenue$199.9M+6.3%

Gross profit$110.3M+1.8%

Operating income$3.7M-89.5%

Net income-$15.1M-226%

EPS (diluted)-$0.46-235%

Balance sheet

Cash & equivalents$150.4M+8.8%

Total debt$5.0M-19.8%

Total equity$311.9M+34.3%

Total assets$2.1B+34.1%

Cash flow

Operating cash flow$71.3M-1.5%

CapEx$496.0K+663%

Free cash flow$70.8M-2.1%

Valuation

Market cap$955.82M-22.5%

Enterprise value$810.41M-26.8%

P/E20×-14.1×

P/S1.2×-0.6×

Profitability

Gross margin60%+3.3pp

Operating margin19.5%+1.1pp

Net margin5.9%+0.8pp

FCF margin40.6%+10.8pp

Returns & leverage

Return on equity17.6%+1.4pp

Debt / equity0×0.0×

Current ratio1×-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InventoryRawMaterials.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 7:34 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001628280-26-053851

Line item	June 30, 2026	December 31, 2025
Raw materials	$36,214	$18,963
Work in process	49,055	15,094
Finished goods	36,054	20,869
Total inventory	$121,323	$54,926

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s raw materials?: Collegium Pharmaceutical, Inc. (COLL) reported raw materials of $36.21M in Q2 2026.
What does raw materials mean?: Unprocessed materials and components purchased for use in manufacturing, valued at cost.

Ask your AI about Collegium Pharmaceutical, Inc.'s raw materials.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk